New targeted drug combo aims to shrink tumors before surgery, spare patients harsh chemo
NCT ID NCT07307287
Summary
This study is testing a new combination of two targeted drugs, SHR-A1811 and pertuzumab, given before surgery for a specific type of breast cancer that is both hormone receptor-positive (HR+) and HER2-positive. The goal is to see if this approach can effectively shrink or eliminate the tumor, potentially avoiding the need for traditional chemotherapy and its side effects. Researchers will monitor patients closely to see how well the treatment works and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.